CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Investor Conference at 2:00 P.M. ET on Monday, Oct. 7, 2024.
The fireside chat will be webcast live and may be accessed here or by visiting Madrigal’s website’s Investor Relations Events page. A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
Now available for licensing, Ultra Soft Nasal Pump Spray leverages innovative spray nozzle chip technology…
Amidst recent news on healthcare pricing, HTL-Strefa, part of the MTD Group, reinforces its commitment…
SHREVEPORT, LA / ACCESSWIRE / October 4, 2024 / Orthodontic patients in Louisiana will soon…
PRINCETON, NJ, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or…
VANCOUVER, Washington, Oct. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"),…
Celebrating 100 years of caring for childrenMONTREAL, Oct. 04, 2024 (GLOBE NEWSWIRE) -- The 36th…